Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2021

Conditions

Coronary Heart Disease

Interventions

DEVICE

Rapamycin target-eluting coronary stent systems (38mm)

Trial Locations (1)

Fu Wai Hospital, Beijing

All Listed Sponsors

lead

Shanghai MicroPort Medical (Group) Co., Ltd.

INDUSTRY

NCT02688842 - Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease | Biotech Hunter | Biotech Hunter